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Abstract: The physico–chemical and biological properties of nanostructured ZnO are combined
with the non-toxic and eco-friendly features of the scCO2-mediated drug loading technique to
develop a multifunctional antimicrobial drug delivery system for potential applications in wound
healing. Two nanostructured ZnO (NsZnO) with different morphologies were prepared through
wet organic-solvent-free processes and characterized by means of powder X-ray diffraction, field
emission scanning electron microscopy (FESEM), and nitrogen adsorption analysis. The antimicrobial
activity of the two samples against different microbial strains was investigated together with the
in vitro Zn2+ release. The results indicated that the two ZnO nanostructures exhibited the following
activity: S. aureus > C. albicans > K. pneumoniae. A correlation between the antimicrobial activity,
the physico–chemical properties (specific surface area and crystal size) and the Zn2+ ion release
was found. Ibuprofen was, for the first time, loaded on the NsZnO carriers with a supercritical
CO2-mediated drug impregnation process and in vitro dissolution studies of the loaded drug were
performed. A successful loading up to 14% w/w of ibuprofen in its amorphous form was obtained.
A preliminary drug release test showed that up to 68% of the loaded ibuprofen could be delivered to
a biological medium, confirming the feasibility of using NsZnO as a multifunctional antimicrobial
drug carrier.
Keywords: Supercritical CO2; ibuprofen; NsZnO; antimicrobial activity
1. Introduction
Zinc oxide (ZnO) is a multifunctional material possessing unique physical and chemical properties,
such as high chemical stability, a high electrochemical coupling coefficient, a broad range of radiation
absorption and high photostability [1]. For these reasons it is largely used in many applications,
ranging from electronics, optoelectronics, sensors and photocatalysis [2,3].
ZnO is also widely used in topical formulations to address several skin conditions, like burns,
scars, and irritations, thanks to its non-toxicity, biocompatibility and antimicrobial activity [4].
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ZnO exhibits three crystal structures named wurtzite, zinc-blend, and an occasionally noticed
rock-salt [5], which allow it to be employed as a nanostructured material for different nanotechnology
applications in many industrial areas, such as gas sensors, biosensors, semiconductors, piezoelectric
devices, field emission displays and photocatalytic degradation of pollutants [6].
Due to the wide spread of nanotechnology, cosmetics and pharmaceuticals have also been
revolutionized. Among all the materials, ZnO has been developed in different nanostructures to
enhance its interaction with the skin and to improve the existing products. A promising application
consists of the addition of ZnO in wound dressing materials. Nanocomposites represent a good
example [7]: they consist of the addition of ZnO nanostructures to polymeric matrices [8–11] in order
to impart novel functionalities, such as antibacterial activity. It is well-established in the literature that
ZnO displays significant bactericidal properties over a broad range of bacteria [12,13]. This occurs
due to several mechanisms, such as generation of reactive oxygen species (ROS), zinc ion release,
membrane dysfunction, and nanoparticle penetration. Moreover the physico–chemical parameters of
the nanomaterial, such as size, morphology, and specific surface area, remarkably affect the antibacterial
properties of ZnO [14,15]. It has also been demonstrated that zinc ion release can improve wound
healing [16,17], since zinc is an essential trace element in the human body and acts as a cofactor in
zinc-dependent matrix metalloproteinases that augment auto debridement and keratinocyte migration
during wound repair.
The treatment of painful wounds is another important issue in biomedicine. It has been
demonstrated that painful wounds can take more time to heal, leading to a lack of compliance
by the patients. Several research works [18] have addressed the development of innovative wound
dressings, able to deliver small doses of anti-inflammatory analgesic drugs to the wound [19]. In this
context the use of ZnO as a drug carrier to be included in the wound dressing device could be of
particular interest thanks to its outstanding biocompatibility, even though the application of this
material as a drug delivery system has not been investigated widely in the literature [20] and may be
considered at its nascent stage.
The use of organic solvents in pharmaceutical technologies is another challenging issue since
it leads both to health concerns, which are related to the toxicity of residual solvents in the final
products, and to a negative environmental impact. In the last decade, supercritical fluid technology
has been emerging as a green drug impregnation method [21]. Supercritical carbon dioxide (scCO2) is
the most used supercritical solvent because it is readily available, cheap, non-toxic, non-flammable,
and recyclable. At the end of the scCO2–mediated drug impregnation process a simple depressurization
step allows a ready-to-use organic-solvent-free drug loaded material to be obtained. Furthermore,
it offers the possibility to tailor the operating parameters of the impregnation process, such as
temperature, pressure, and time, on the basis of the selected drug/carrier system [22]. This permits a
better drug/carrier interaction to be obtained, with the drug in an amorphous state, which improves
its dissolution profile and, consequently, its bioavailability [23].
Notwithstanding the above reported remarkable advantages, some drawbacks in the use of this
technology have emerged, such as the scarce ability of scCO2 to dissolve polar and ionic species,
since it is a linear molecule with no net dipole moment. Furthermore, the elevated pressure required
and high maintenance cost can represent a limitation in the use of this technology [21].
Even though the incorporation of active pharmaceutical ingredients (APIs) in organic and
inorganic carriers through scCO2 has been proposed in different research areas [22,24,25], the loading
of drugs on ZnO carriers has not been investigated yet [23] and, to the best of our knowledge,
the clotrimazole incorporation described in our previous work [26] represents the very first study
about the loading of an API on nanostructured ZnO by means of scCO2.
The fundamental idea of this research project is to combine the physico–chemical and biological
properties of ZnO with the eco-friendly features of the scCO2–mediated drug impregnation process to
develop a green multifunctional device for treating painful wounds. This consists of the combination
of antibacterial and anti-inflammatory/analgesic action in a single delivery system. ZnO is particularly
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suitable for this role, because its nanostructure can be tailored to host drug molecules and because
it can offer intrinsic antimicrobial activity [15]. Ibuprofen (IBU) has been selected as the drug to be
hosted in the ZnO nanostructures, since it is one of the most commonly used and most frequently
prescribed non-steroidal anti-inflammatory drug (NSAID) for oral and topical administration due to its
prominent analgesic role [27,28], and it has already been employed to prepare innovative pain-reducing
wound dressings [18,19]. Furthermore IBU has also been widely used in many scCO2–mediated drug
impregnation processes [23].
This work is a feasibility study aiming at investigating the possibility of loading IBU on different
ZnO carriers by means of scCO2 and checking the antimicrobial activity as well as the capability
of the obtained system to release Zn2+ ions and the drug, which are essential requirements for the
development of a multifunctional device for wound healing applications. Two nanostructured ZnO
(NsZnO) powders with different morphologies and physico–chemical parameters were synthetized
through wet organic-solvent-free processes [26] and characterized by means of powder X-ray
diffraction, FESEM images, and nitrogen adsorption analysis. The samples were also characterized
from a biological point of view; particularly, their antimicrobial activity against different microbial
strains and the in vitro Zn2+ release profiles from the NsZnO matrices were evaluated. IBU was loaded
on the NsZnO carriers with a scCO2–mediated drug impregnation process and in vitro dissolution
studies of the loaded drug were performed.
2. Materials and Methods
2.1. Materials
All the reagents for chemical synthesis, as well as ibuprofen, were purchased from Sigma-Aldrich
and used as received without further purification. Carbon dioxide with a purity of 99.998% was
supplied by SIAD (Italy). Bidistilled water was used throughout this study.
2.2. Synthesis of Nanostructured ZnO (NsZnO)
Two different NsZnO materials were synthesized as previously described [26], using two different
organic solvent free processes: the first one was based on the use of sole water as the solvent,
i.e., a chemical bath deposition (NsZnO-1) method, while the second was a soft-template sol–gel
synthesis method (NsZnO-2).
2.3. Drug Adsorption from Supercritical Carbon Dioxide
The scCO2–mediated drug loading was carried out using a procedure that had been developed
in previous works [26,29]. It consisted of contacting the drug and each of the two NsZnO materials
in a static atmosphere of scCO2 at constant temperature and pressure (Figure 1). First, a pellet of the
drug (100 mg) and a pellet of the NsZnO (100 mg) were prepared and introduced into a glass cylinder
of 1 cm diameter. A disc of filter paper was placed between the two pellets to prevent their contact
and guarantee an efficient recovery of the samples at the end of the drug loading process. The glass
cylinder was placed inside a stainless-steel vessel, which was put in an oven that kept the entire system
at constant temperature. Liquid CO2 was used to fill the vessel, then the temperature was increased
to 35 ◦C and additional CO2 was pumped to reach the target pressure (10 MPa). The pump was
coupled with a cryogenic bath to prevent cavitation. The system was maintained at the above-reported
conditions for 12 h. At the end of the drug loading process, the on–off valve was opened, and the
apparatus was brought back to atmospheric pressure by means of a heated restrictor valve.
The IBU-containing materials are denoted hereafter as IBU@NsZnO-1 and IBU@NsZnO-2.
Moreover, the two carriers as such were treated in the same conditions in the absence of IBU in
the glass cylinder, in order to investigate the effect of the scCO2 treatment on the NsZnO samples.
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2.4. Morphological Characterization
FESEM images were r corded with a FESEM Zeiss Merlin instrument, equipped wit an EDS
detector (Oxford Instruments, Abingdon-on-Thames, UK).
2.5. Powder X-ray Diffractometry
XRD patterns were obtained using a Panalytical X’Pert (Cu Kα radiation, Almelo, The Netherlands)
diffractometer. Data were collected with a 2D solid state detector (PIXcel) from 20 to 70 2θ with a step size
of 0.001 2θ and a wavelength of 1.54187 Å.
2.6. Nitrogen Adsorption Analysis
Nitrogen adsorption isotherms were measured using a Quantachrome AUTOSORB-1 instrument
(Boynton Beach, FL, USA). Before the adsorption measurements, samples were outgassed for 2 h at
100 ◦C. BET specific surface areas (SSABET) were calculated in the relative pressure range of 0.04–0.1.
2.7. Thermogravimetry Analysis
Thermogravimetry (TG) analyses were carried out between 20 ◦C and 800 ◦C in air (flow rate
100 mL/min with a heating rate of 10 ◦C/min) using a SETARAM 92 instrument (Caluire et Cuire, France).
2.8. Antimicrobial Activity of NsZnO
2.8.1. Microbial Strains and Culture Conditions
The antibacterial activity of NsZnO-1 and NsZnO-2 was tested against a Gram-positive and a
Gram-negative bacterial strain, such as Staphylococcus aureus ATCC 29213 and Klebsiella pneumoniae
ATCC 700603, respectively. The antifungal activity of NsZnO-1 and NsZnO-2 samples was investigated
against Candida albicans ATCC 90023. The strains were purchased from American Type Culture
Collection (ATCC) (Manassas, VA, USA).
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2.8.2. Inocula Preparation
Microorganism inocula were prepared by picking two to three colonies from an overnight culture
of S. aureus/K. pneumoniae on Brain heart infusion agar (BHA, Merck KGaA, Darmstadt, Germany) or
of C. albicans on Sabouraud dextrose (SAB, Merck KGaA, Darmstadt, Germany) agar at 37 ◦C (bacteria)
or 35 ◦C (yeasts), suspending them in 5 mL of 0.85% normal saline, to yield a 0.5 McFarland turbidity
standard, corresponding to a suspension of ~5 × 108 CFU/mL for bacteria or 5 × 106 CFU/mL
for yeasts.
Bacterial suspensions were diluted 1:1000 in Mueller Hinton broth (MHB, Merck KGaA,
Darmstadt, Germany) to obtain a final concentration of 105 CFU/mL. Fungal suspension was diluted
1:1000 in RPMI-1640 without sodium bicarbonate and with L-glutamine (Invitrogen, San Giuliano
Milanese, Milano, Italy), buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid (MOPS)
(Sigma-Aldrich, Milan, Italy), and supplemented with glucose 0.2%, to obtain a concentration of
103 CFU/mL. Inocula were confirmed by colony counts in duplicate.
2.8.3. In Vitro Antimicrobial Assays
Determination of Minimum inhibitory concentration (MIC), Minimum bactericidal concentration
(MBC), and Minimum fungicidal concentration (MFC).
The antimicrobial activity of NsZnO-1 and NsZnO-2 was determined using a broth microdilution
(BM) method susceptibility assay, according to Clinical and Laboratory Standard Institute guidelines
(CLSI document M07-A9 for bacteria, and M27-A3 for yeasts) [30,31]. As guidelines were not available
for susceptibility testing of NsZnO, the antimicrobial activity was assessed following the CLSI BM
method, with some modifications.
MIC determination was performed by serial dilution using 96-well microtiter plates (Sarstedt,
Milan, Italy). Stock suspensions of NsZnO prepared at 30,000 µg/mL (w/v) in phosphate buffered
solution (PBS; pH 7.4) were dispersed for 1 h using an ultrasonic bath, in order to minimize
sedimentation of NsZnO particles. Doubling dilutions of the ZnO ranging from 15,000 to 30 µg/mL
were prepared in 96-well microtiter plates in MHB for bacteria or in RPMI-1640 with MOPS for yeasts.
After inoculum addition (0.1 mL), the plates were incubated under normal atmospheric conditions
at 37 ◦C (bacteria) or 35 ◦C (yeasts) for 24 h. A sterile medium incubated under the same conditions
was used as a blank, while the medium inoculated with the target microorganisms (without NsZnO)
was used as a positive control of growth. All determinations were performed in duplicate. The lowest
concentration of the NsZnO showing complete inhibition of visible growth was defined as MIC.
MBC and MFC of NsZnO were determined by subculturing 10 µL of broth taken from all the
wells without visible growth onto BHA (bacteria) or SAB (yeasts) agar plates that did not contain the
test agents. After incubation for 24 h at 37 ◦C (bacteria) or 35 ◦C (yeasts), MBC or MFC were defined as
the lowest concentration of ZnO resulting in the death of 99.9% of the inoculum in no subculture [32].
Viable microorganism counts
To assess the antimicrobial activity of NsZO over time, the number of viable microorganisms was
measured by monitoring bacterial/fungal growth after 24 h [33].
Briefly, the bacterial or yeast cells were grown overnight in BHI (Merck KGaA) or Sabouraud
Dextrose (SAB, Merck KGaA, Darmstadt, Germany) broth at 37 ◦C or 35 ◦C, respectively. Bacteria
and/or yeasts were harvested by centrifugation, washed, suspended in PBS, and diluted to yield a
stock suspension of ~5 × 105 CFU/mL. All the NsZnO samples with concentration of 15,000 µg/mL,
suspended in PBS, were incubated with bacterial or yeast suspension in a shaker incubator at 37 ◦C or
35 ◦C, respectively, for 24 h. PBS solution was used as a negative control. All samples were serially
diluted and 100 µL of bacterial/yeasts suspension was drawn from each sample tube, spread on BHA
or SAB agar plates, and incubated at 37 ◦C or 35 ◦C for 24 h, so that the number of CFU/mL could
be determined.
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2.9. In Vitro Zinc Ions Release
Zinc ion release from the samples NsZnO-1 and NsZnO-2 was studied using vertical Franz
diffusion cells and synthetic skin (Dow Corning, 7-4107, Silicone Elastomer Membrane, Biesterfeld
Polychem, Milan, Italy). Suspensions of NsZnO (5 mg of powder in 0.5 mL of PBS buffer solution)
were employed as the donor phases. The receiving phase consisted of a PBS buffer solution at pH 7.4.
The apparatus was maintained under stirring at 33 ◦C, during which, at scheduled time intervals,
the receiving phase was withdrawn and entirely substituted with a fresh receiving phase. Zinc ion
quantification was performed in each withdrawn sample using inductively coupled plasma mass
spectrometry (ICP-MS, Thermo Scientific, Waltham, MA, USA).
2.10. Preliminary In Vitro Drug Release Study
The ability of the IBU-loaded NsZnO to release IBU was tested by using a multicompartment
rotating cell equipped with a hydrophilic dialysis membrane (Spectra/Por, Spectrum®, cut-off
12,000–1,4000 Da, Sigma-Aldrich, Milan, Italy). PBS solution (1 mL) was used as the receiving medium.
At predetermined time intervals, the receiving phase was completely replaced by a fresh solution,
and analyzed for IBU content at 263 nm, using a Beckman–Coulter DU 730 Spectrophotometer
(Indianapolis, IN, USA).
3. Results and Discussion
Figure 2 shows the FESEM pictures of NsZnO-1 and NsZnO-2. As observed in the previous
study [26], the two carriers were characterized by different morphologies.
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NsZnO-1 appeared in the form of aggregates of nanosheets, with a thickness of about 20 nm,
that were formed by the self-assembling of ovoid nanoparticles (having sizes around 15–20 nm).
This morphology is in agreement with the mechanism growth proposed by Kakiuchi et al. [34].
The morphology of NsZnO-2 consisted of micrometric and sub-micrometric aggregates of
nanoparticles with heterogeneous sizes of tens of nanometers.
Primary nanoparticles of NsZnO-1 were definitely smaller than those of NsZnO-2. The values
of BET specific surface area and pore volume obtained by nitrogen adsorption are shown in Table 1.
As previously observed [26], both features were larger for NsZnO-1 (68 m2/g and 0.230 cm3/g,
respectively) than for NsZnO-2 (12 m2/g and 0.050 cm3/g, respectively), due to the lower particles
size of NsZnO-1.
Table 1. Specific surface area (SSA) and pore volume values before and after the ibuprofen (IBU)
adsorption by scCO2 process.
Before IBU Adsorption After IBU Adsorption
SSABET (m2/g) Pore Volume (cm3/g) SSABET (m2/g) Pore Volume (cm3/g)
NsZnO-1 68 0.230 8 0.04
NsZnO-2 12 0.050 nil nil
Figure 3 reports the XRD patterns of both NsZnO materials, which reveal the occurrence of a
highly crystalline single hexagonal phase of a wurtzite structure (JCPDS ICDD 36-1451). Comparing
the XRD patterns of the two samples, it is evident that NsZnO-1 showed broader peaks than NsZnO-2,
in agreement with the smaller particles size evidenced by FESEM analyses.
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In order to investigate the stability of NsZnO carriers in scCO2, the XRD patterns of NsZnO-1 and
NsZnO-2 after treatment in scCO2 for 12 h, at 35 ◦C and 10 MPa, were collected and these are reported
in Figure 4. In both cases the hexagonal wurtzite pattern of ZnO was preserved, and no new peaks
were detected. This result showed that no extensive reaction between ZnO and the CO2 occurred,
which should not have been taken for granted, considering that the reaction between ZnO and CO2
to give ZnCO3 is a well-kno n phenomenon [35,36]. This evidence confirms the feasibility of using
scCO2 as a solvent for the drug loading of NsZnO carriers.
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As far as the IBU loading is concerned, its content was calculated as the weight loss by TG analysis
(Figure S1) and was found equal to 14% w/w for IBU@NsZnO-1 and 9% w/w for IBU@NsZnO-2,
respectively (Table 2).
Table 2. Ibuprofen content in IBU@NsZnO-1 and IBU@NsZnO-2.
IBU Content (% w/w)
IBU@NsZnO-1 14
IBU@NsZnO-2 9
The l IBU content in IBU@NsZnO-1 than in IBU@NsZnO-2 was ascribed to the larger specific
surface area and pore volume of NsZnO-1, which yielded larger rug adsorption and l adi g capacity.
Due to the presence of IBU molecules on the NsZnO carriers, the specific surface area and pore
volume drastically decr ased in both systems, as revealed by the data reported in Table 1.
It is worth noting th t IBU contents in the two syst ms wer similar t those previously obtained
for clotrimazole adsorbed by scCO2 on NsZnO-1 and NsZnO-2 carriers [26], which were equal to 17%
w/w and 14% w/w, respectively. This suggests the robustness of the scCO2 approach in the drug
loading of NsZnOs.
XRD analyses were carried out to characterize IBU@NsZnO-1 and IBU@NsZnO-2. Figure 5 reports
the patterns of both syst ms, in comparison with those of the materials as- uch and the pure
crystallin IBU. No additi nal diffraction peaks typical of the crystalline IBU w e observed for eit r
IBU@NsZnO-1 or IBU@NsZnO-2 samples. This reveals th t drug molecu es are not assembled in the
crystalline form on the two carriers.
The ame result was pr viously obtained in the case of clotrimazole [26]. The amorphous form of
the drug adsorbed on N ZnO from scCO2 may be as ribed to the scCO2–mediated pr cess, which is
known to favor th amorphization of the adsorbed drug [23]. This is a crucial aspect, in particular for
poorly water-solubl drugs, because it is widely accepted that amorphization of the drug molec les
plays a key role in increasing their dissolution rate and solubility.
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In order to investigate the antimicrobial activity of NsZnOs, some microbiological parameters,
such as MIC, MBC, and MFC were used (Table 3). In addition, a CFU assay was used to measure the
antimicrobial activity of the NsZnOs over time by monitoring bacterial/fungal growth within 24 h
(Table 4, and Figure 6).
Table 3. Minimum inhibitory concentration (MIC), and minimum bactericidal concentration (MBC),
of NsZnO-1 and NsZnO-2 determined for S. aureus, K. pneumoniae, and C. albicans expressed in µg/mL.
Minimum fungicidal concentration (MFC) for C. albicans was not determined.
Microbial Strain S. aureus K. pneumoniae C. albicans
MIC (µg/mL) MBC (µg/mL) MIC (µg/mL) MBC (µg/mL) MIC (µg/mL)
NsZnO-1 120 >470 470 1875 >15,000
NsZnO-2 230 >470 930 >3750 >15,000
s e erged fro ata s o n in l tr t r s i ite a str er
activity on the Gram-pos tive S. aureus than the Gram-negative K. pneumoniae. B twe n the two
ZnO nanostructures, NsZnO-1 showed be ter ac ivity tha NsZnO-2 against S. aureus with an MIC
value of 120 µg/mL vs 230 µg/mL. Si ce ZnO suspensions ppeared “cloudy” in the case of C. albicans,
it was not possible to determine the MIC from the visual appearance of the medium; hence, MFC
was not assessed for thi yeast (da a n t shown). In general, MBCs were two concentrations higher
than MICs, with exception of NsZnO-2 that showed a MBC value one concentration higher than I
a ai st . a re s, ti
Figure 6 report he results of the viable microo ganism counts as es ed through a CFU
assay. The bactericidal activity of NsZnO-1 against S. aureus (expressed in Log CFU/mL) was greater
than that chieved by NsZnO-2 (1 vs 4.2 , Figure 6a). The same trend, even if with l ss microbial load
reduct on v lues, is evident in Figure 6b for K. pneumoniae, where the Log CFU/mL of bacterial load
was 7.21 an 8.42 for NsZnO-1 and -2, respectively. D ite the failure of the broth dilution
technique f r y asts, the enumeration of viabl orga isms’ method was efficient in the determi ation of
the ant fungal activity. The resu ts are shown in Figure 6c. NsZnO-1 log counts observed for C. albicans
was 5.27, whereas NsZnO-2 was abl to reduce the ye t cells growth of 6.15 log in comparison with
ZnO-free contr ls (7.02 log). Taken together, these results indica e that the two ZnO nanostruc ures
exhibited a bette a ivity towards S. aureus than K. pneumoniae and C. albic s.
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Table 4. Comparison of antibacterial/antifungal activity of NsZnO-1 and NsZnO-2 against S. aureus,
K. pneumoniae, and C. albicans determined with the enumeration of viable microorganism assay and
expressed in CFU/mL after 24 h of incubation.
Microbial Strain S. aureus K. pneumoniae C. albicans
NsZnO-1 10 CFU/mL 1.62 × 107 CFU/mL 1.85 × 105 CFU/mL
NsZnO-2 1.65 × 104 CFU/mL 2.66 × 108 CFU/mL 1.43 × 106 CFU/mL
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ur data are difficult to co pare due to the different ethods and icroorganis s used in the
anti icrobial activity determination. However, these data are in agreement with those of some authors
who detected a better antimicrobial activity of ZnO-compounds on Gram positive than Gram negative
bacteria, and a good antifungal activity on C. albicans [13,37,38].
In addition, our results agree with the conclusions of Reddy et al. [39] and Tayel et al. [40]
and disagree with the conclusions of Pasquet et al. [14]. In detail, Reddy and Tayel explained that
the peptidoglycan cell-wall of Gram-positive bacteria may promote ZnO attachment onto the cell
all, whereas cell-wall lipophilic components of Gram-negative bacteria may oppose this attach ent.
ntil no , the antifungal activity echanis has not been ell clarified; ho ever, the candidacidal
echanis of Zn can be probably ascribed to the cellular structure disruption or to inhibition of
biological olecular synthesis due to Zn2+ release [38].
ong the sZn s investigated, the sa ple sZn -1 sho ed higher anti icrobial activity
co pared to sZn -2. This trend as confir ed by both the in vitro tests. This pheno enon could
be ascribed to the crystallite sizes of the nanoparticles, hich have been reported to greatly i pact
their antimicrobial activity, probably because of a greater accumulation of the nanoparticles inside the
cell membrane and cytoplasm [12]. In fact, NsZnO-1 is characterized by lower crystallite sizes than
NsZnO-2. This observation can be reinforced by the results obtained with C. albicans, against which
NsZnO-1 showed better antifungal activity than NsZnO-2. These conclusions are consistent with the
study of Lipovsky et al. [41], who suggested that ZnO nanoparticles display a marked activity against
C. albicans and that the cytotoxic effect is size dependent.
ong the key echanis s influencing the anti icrobial activity of nanostructured Zn , it is
i portant to consider the release of Zn2+ ions.
For this reason, a si ple test as carried out to study the zinc ion release fro s n -1 and
sZn -2 using vertical Franz diffusion cells equipped with synthetic skin. The results drawn from the
zinc ion quantification are shown in Figure 7. The in vitro Zn2+ release study evidenced the ability
of both the sZn s to release Zn2+, highlighting their potential use as ultifunctional anti icrobial
drug carriers.
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The in vitro ibuprofen release study was aimed at verifying the possibility of releasing the drug
from IBU@NsZnO-1 and IBU@NsZnO-2 systems, assessing the lack of complete irreversible trapping of
drug molecules in the carrier. The same test was carried out with crystalline ibuprofen for comparison.
Figure 8 shows the cumulative release curves of ibuprofen. The percentage of drug released in 6 h
was 68% for IBU@NsZnO-2, 44% for IBU@NsZnO-1, and 57% for crystalline ibuprofen.
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These data reveal that both NsZnO-1 and NsZnO-2 were able to act as carriers for ibuprofen
delivery. The different percentage of IBU released from the two materials may be ascribed to the
different morphology and pore volume, which affect the distribution of drug molecules in the carrier
and their diffusion to the receiving solution.
In conclusion, this preliminary in vitro release test showed that ibuprofen adsorbed on the
NsZnO-1 and NsZnO-2 by scCO2 can be delivered, confirming the potential role of these nanostructures
as drug delivery systems, as previously observed in the case of clotrimazole [26].
4. Conclusions
A feasibility study was conducted to investigate the possibility of developing a green multifunctional
device for wound healing applications. Two multifunctional drug delivery systems based on
nanostructured ZnO were prepared by means of non-toxic and organic-solvent free procedures.
The antimicrobial properties of the ZnO carriers were investigated against both Gram-positive
and Gram-negative bacterial strains, such as S. aureus and K. pneumoniae, as well as against C. albicans.
As a whole, the results indicated that the two ZnO nanostructures exhibited the following activity:
S. aureus > C. albicans > K. pneumoniae.
Moreover, an in vitro Zn2+ release study was carried out. A correlation between the antimicrobial
activity, the physico–chemical properties (specific surface area and crystal size) of nanostructured ZnO
and the Zn2+ ion release was found.
For the first time ibuprofen was successfully loaded on the nanostructured ZnO carriers with
a supercritical CO2-mediated drug impregnation process. The drug-loaded amount was observed
to depend on the specific surface area and the pore volume of the carrier and up to 14% w/w of
ibuprofen in its amorphous form was obtained inside the final drug delivery system. A preliminary
drug release test showed that up to 68% of the loaded ibuprofen could be delivered to a biological
medium, confirming the feasibility of using nanostructured ZnO as a multifunctional antimicrobial
drug carrier.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-4991/9/3/407/
s1, Figure S1: Section A: TG curves of NsZnO-1 and IBU@NsZnO-1; Section B: TG curves of NsZnO-2 and
IBU@NsZnO-2.
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